The EPA sets out the following criteria for efficacy against Covid-19:
1. The product must be a hospital or broad-spectrum disinfectant product registered with EPA.
2. For an emerging enveloped virus, the product must have acceptable efficacy data previously submitted to and reviewed by the Agency against one non-enveloped virus (Poliovirus).
The Rejuvenate™ line of disinfectants (concentrate, ready-to-use and premoistened wipes) have demonstrated effectiveness against viruses similar to Covid-19 on hard, nonporous surfaces. Therefore, Rejuvenate can be used against 2019-nCoV when used in accordance with the directions for use against Poliovirus type 1 on hard, non-porous surfaces. Referent to January 27,